New implant aims to tame glaucoma with one dose
NCT ID NCT05822245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new implant called PER-001 placed inside the eye to treat open-angle glaucoma. The trial included 33 adults and checked for safety and how well it controlled eye pressure. The implant is designed to release medication over time, potentially reducing the need for daily eye drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PER-001 intravitreal implant
- What this could lead to
- If successful, this implant could offer a new way to lower eye pressure and help control glaucoma with a single dose.
- What could go wrong
- This is an early-phase trial with only 33 people, so safety and effectiveness are not yet proven. The implant may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPEN-ANGLE GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perfuse Therapeutics, Inc.
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye test match the gold standard for glaucoma?
- Which laser best tames glaucoma pressure?
- Could a single eye implant replace years of glaucoma drops?
- Eye implant could offer long-term pressure control for glaucoma patients
- Glaucoma implant MINIject put to the test in everyday eye clinics
- Glaucoma implant could replace daily eye drops